9-Phenanthrol, a TRPM4 inhibitor, protects isolated rat hearts from ischemia-reperfusion injury

PLoS One. 2013 Jul 25;8(7):e70587. doi: 10.1371/journal.pone.0070587. Print 2013.

Abstract

Despite efforts to elucidate its pathophysiology, ischemia-reperfusion injury lacks an effective preventative intervention. Because transient receptor potential cation channel subfamily M member 4 (TRPM4) is functionally expressed by many cell types in the cardiovascular system and is involved in the pathogenesis of various cardiovascular diseases, we decided to assess its suitability as a target of therapy. Thus, the aim of this study was to examine the possible cardioprotective effect of 9-phenanthrol, a specific inhibitor of TRPM4. Isolated Langendorff-perfused rat hearts were pretreated with Krebs-Henseleit (K-H) solution (control), 9-phenanthrol, or 5-hydroxydecanoate (5-HD, a blocker of the ATP-sensitive potassium channel) and then subjected to global ischemia followed by reperfusion with the K-H solution. To evaluate the extent of heart damage, lactate dehydrogenase (LDH) activity in the effluent solution was measured, and the size of infarcted area of the heart was measured by 2,3,5-triphenyltetrazolium chloride staining. In controls, cardiac contractility decreased, and LDH activity and the infarcted area size increased. In contrast, in hearts pretreated with 9-phenanthrol, contractile function recovered dramatically, and the infarcted area size significantly decreased. The cardioprotective effects of 9-phenanthrol was not completely blocked by 5-HD. These findings show that 9-phenanthrol exerts a cardioprotective effect against ischemia in the isolated rat heart and suggest that its mechanism of action is largely independent of ATP-sensitive potassium channels.

MeSH terms

  • Animals
  • Anti-Arrhythmia Agents / pharmacology
  • Biomarkers / metabolism
  • Cardiotonic Agents / pharmacology*
  • Decanoic Acids / pharmacology
  • Enzyme Inhibitors / pharmacology*
  • Glucose
  • Heart / drug effects*
  • Heart / physiopathology
  • Hydroxy Acids / pharmacology
  • In Vitro Techniques
  • KATP Channels / antagonists & inhibitors
  • KATP Channels / metabolism
  • L-Lactate Dehydrogenase / metabolism
  • Male
  • Myocardial Contraction / drug effects
  • Myocardial Reperfusion Injury / drug therapy*
  • Myocardial Reperfusion Injury / metabolism
  • Myocardial Reperfusion Injury / physiopathology
  • Phenanthrenes / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Severity of Illness Index
  • TRPM Cation Channels / antagonists & inhibitors*
  • TRPM Cation Channels / metabolism
  • Tromethamine

Substances

  • Anti-Arrhythmia Agents
  • Biomarkers
  • Cardiotonic Agents
  • Decanoic Acids
  • Enzyme Inhibitors
  • Hydroxy Acids
  • KATP Channels
  • Krebs-Henseleit solution
  • Phenanthrenes
  • TRPM Cation Channels
  • TRPM4 protein, rat
  • Tromethamine
  • 5-hydroxydecanoic acid
  • 9-phenanthrol
  • L-Lactate Dehydrogenase
  • Glucose

Grants and funding

The authors have no support or funding to report.